Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Doxycycline, Temozolomide and Ipilimumab in Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Doxycycline
Drug: Ipilimumab
Drug: Temozolomide

First Posted Date: 2012-05-02

Last Posted Date: 2020-09-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT01590082

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

Phase 1

Active, not recruiting

Conditions: Metastatic Malignant Neoplasm in the Lung
Metastatic Melanoma
Metastatic Osteosarcoma
Metastatic Renal Cell Cancer
Sarcoma
Stage IV Cutaneous Melanoma AJCC v6 and v7
Stage IV Osteosarcoma AJCC v7
Stage IV Renal Cell Cancer AJCC v7

Interventions: Biological: Aerosolized Aldesleukin
Other: Laboratory Biomarker Analysis

First Posted Date: 2012-05-02

Last Posted Date: 2025-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT01590069

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Phase 2

Completed

Conditions: Stage IV Uveal Melanoma AJCC v7
Metastatic Uveal Melanoma

Interventions: Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Biological: Nivolumab

First Posted Date: 2012-04-25

Last Posted Date: 2024-07-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 67

Registration Number: NCT01585194

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

Phase 1

Terminated

Conditions: Brain Neoplasms
Central Nervous System Neoplasms

Interventions: Drug: TPI287
Drug: Bevacizumab

First Posted Date: 2012-04-20

Last Posted Date: 2019-06-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT01582152

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Neoplasm
Metastatic Malignant Neoplasm
Recurrent Malignant Neoplasm
Refractory Malignant Neoplasm

Interventions: Drug: Everolimus
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Vandetanib

First Posted Date: 2012-04-20

Last Posted Date: 2025-01-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 153

Registration Number: NCT01582191

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Non-Hodgkins Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Leukemia
Myeloproliferative Diseases
Acute Lymphocytic Leukemia
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia
Hodgkins Lymphoma

Interventions: Drug: Fludarabine monophosphate
Drug: Busulfan
Procedure: Stem Cell Infusion
Drug: Tacrolimus
Drug: Methotrexate
Drug: G-CSF

First Posted Date: 2012-04-06

Last Posted Date: 2023-06-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 201

Registration Number: NCT01572662

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: Ponatinib

First Posted Date: 2012-04-04

Last Posted Date: 2025-03-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT01570868

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Withdrawn

Conditions: Chemotherapeutic Agent Toxicity
Lung Cancer

Interventions: Drug: Carboplatin
Drug: Docetaxel
Drug: Anvirzel
Behavioral: Questionnaires

First Posted Date: 2012-03-23

Last Posted Date: 2015-06-08

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01562301

Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Oxaliplatin
Drug: Irinotecan
Drug: 5-FU
Drug: Gemcitabine
Radiation: Radiation Therapy

First Posted Date: 2012-03-22

Last Posted Date: 2020-08-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT01560949

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Neoplasm
Castleman Disease
Digestive System Carcinoma
Erdheim-Chester Disease
Lip and Oral Cavity Carcinoma
Lymphangioleiomyomatosis
Malignant Endocrine Neoplasm
Malignant Female Reproductive System Neoplasm
Malignant Male Reproductive System Neoplasm
Malignant Neoplasm

Interventions: Biological: Bevacizumab
Biological: Cetuximab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Valproic Acid
Drug: Temsirolimus

First Posted Date: 2012-03-13

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 155

Registration Number: NCT01552434

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy